Day One Biopharmaceuticals, Inc. Forecasted to Post Q3 2024 Earnings of ($0.69) Per Share (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at HC Wainwright boosted their Q3 2024 EPS estimates for Day One Biopharmaceuticals in a report released on Tuesday, May 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.69) per share for the quarter, up from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($2.74) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $1.24 EPS.

DAWN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $16.41 on Thursday. The company has a 50 day moving average price of $15.46 and a 200 day moving average price of $14.19. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -6.89 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07).

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors have recently made changes to their positions in DAWN. First Turn Management LLC acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth $24,834,000. TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals by 45.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock valued at $24,325,000 after purchasing an additional 523,455 shares during the last quarter. Braidwell LP boosted its stake in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after purchasing an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after buying an additional 472,654 shares during the last quarter. Finally, Superstring Capital Management LP bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $5,543,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the sale, the chief financial officer now directly owns 277,754 shares in the company, valued at approximately $4,235,748.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. Insiders have sold a total of 195,247 shares of company stock valued at $3,376,817 in the last three months. Company insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.